Heart disease in India doesn’t behave like heart disease in most of the world it’s usually compared against. Indians tend to present with coronary artery disease roughly five to ten years earlier than Western populations, at smaller vessel calibres, and with a disease pattern that’s more diffuse and harder to treat with a single, simple intervention. That combination — a younger, larger, and clinically more complex patient population — is exactly why India’s cardiovascular devices market has become one of the most closely watched segments in Indian MedTech, and why the next five years look set to reshape it meaningfully.
The Market, By the Numbers
Ask different research firms to size India’s cardiovascular devices market and you’ll get a genuinely wide spread of answers — a reflection of how differently “cardiovascular devices” gets scoped across studies, not a sign that any one estimate is unreliable. IMARC Group puts the market at USD 2.33 billion in 2025, growing to USD 4.14 billion by 2034 at a 6.6% CAGR. Mordor Intelligence estimates USD 1.55 billion in 2025, reaching USD 2.34 billion by 2030 at 8.64% CAGR. TechSci Research and ResearchAndMarkets both converge closer to USD 1.6 billion in 2024, growing to roughly USD 2.4 billion by 2030 at just over 7% CAGR. BlueWeave’s more conservative estimate starts lower, at USD 0.91 billion in 2023, but projects a steeper 9.15% CAGR through 2030.
Read across these, the consistent signal is a market currently sitting somewhere in the USD 1.5–2.3 billion range, on a trajectory to roughly double by the early-to-mid 2030s, with most estimates clustering around a 6–9% CAGR — comfortably within the range cited in industry commentary on the sector’s growth trajectory. Certain sub-segments are growing considerably faster than that blended average: structural heart devices — TAVR (transcatheter aortic valve replacement), mitral repair, and left atrial appendage closure — are projected to grow at nearly 20% CAGR through 2030, and peripheral vascular devices at around 9.7% CAGR, making these the standout high-growth categories within the broader cardiovascular device space.
Why the Disease Burden Keeps Growing
The demand side of this market isn’t speculative — it’s driven by a disease burden that’s both large and structurally difficult. Cardiovascular disease already contributes 14.1% of India’s national disability-adjusted life years (DALYs), double what it was in 1990, and ischemic heart disease and stroke cases have risen 2.3-fold over the same period. India’s elderly population is projected to reach 22.5% of residents by 2051, adding a straightforward demographic tailwind on top of the disease trend itself.
But the more distinctive driver — and the one that separates India’s cardiovascular device story from most other large markets — is the younger age of onset. Research through the CAD in the Young (CADY) registry found young Indian patients presenting with acute coronary syndrome at a mean age of 49, with diabetes present in 44% and hypertension in 49% of cases studied. Globally, South Asia records the highest regional share of first heart attacks occurring before age 40, at 9.7% — and Indian-specific studies have found coronary artery disease in individuals under 40 accounts for a meaningfully higher share of angiographic cases than seen in Western data. The average age of onset for cardiovascular disease among Indians runs 5 to 10 years earlier than global populations, driven by a combination of genetic predisposition, earlier-onset metabolic risk factors, and rapidly changing urban lifestyles.
That younger-onset pattern has a direct commercial implication for the device industry: a patient diagnosed with coronary artery disease at 45 rather than 65 represents a longer lifetime treatment relationship — more repeat procedures, longer-term device durability requirements, and a growing need for devices designed around smaller, more diffusely diseased Indian coronary anatomy specifically, rather than simply importing device designs optimised for older Western patients.
The Shift Toward Minimally Invasive Procedures
Across nearly every cardiovascular sub-segment, the clinical trend is the same: open surgical procedures giving way to catheter-based, minimally invasive alternatives. Percutaneous coronary intervention (angioplasty and stenting) remains the backbone of coronary artery disease management, but the more striking growth is happening in structural heart intervention — TAVR specifically has emerged as the largest revenue-generating structural heart device category, with real clinical uptake already visible on the ground: S.L. Raheja Hospital in Mumbai completed its 50th TAVR procedure in May 2025, a milestone that would have been unusual for an Indian hospital outside a handful of flagship cardiac centres just a few years earlier.
Left atrial appendage closure (LAAC) — a catheter-based alternative to long-term blood thinners for atrial fibrillation patients at stroke risk — has been flagged as the fastest-growing structural heart device sub-segment in India specifically. Ablation technologies, used to treat cardiac arrhythmias by selectively destroying the small areas of heart tissue generating abnormal electrical signals, are following a similar minimally invasive growth trajectory, part of the same broader shift toward catheter-based intervention across nearly every cardiovascular disease category.
AI-Enabled Imaging and Precision Tools
Diagnostic and monitoring devices already represent the largest single segment of India’s cardiovascular devices market, and increasingly, the technology inside that segment is AI-assisted rather than purely mechanical. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) — imaging techniques that let interventional cardiologists see inside a coronary artery in far greater detail than a standard angiogram — are becoming more central to complex procedure planning, part of a broader trend toward precision-guided intervention that pairs advanced imaging with catheter-based treatment.
This mirrors a pattern already well underway across Indian MedTech more broadly: AI-assisted diagnostic tools moving from pilot deployments into genuine clinical infrastructure, as seen in AI-based chest X-ray screening and the government’s own “AI in MedTech” roadmap, which has specifically flagged diagnostics as the first major opportunity for scaled AI adoption in Indian healthcare. Cardiology — with its heavy reliance on image interpretation, from echocardiograms to angiograms to CT coronary angiography — is a natural, high-value extension of that same trend.
Policy Tailwinds: PLI, Domestic Manufacturing, and Import Substitution
The clinical and demographic drivers above would matter less without a manufacturing and policy environment actively working to make advanced cardiovascular devices more available and more affordable inside India. The Production Linked Incentive (PLI) scheme for medical devices — covered extensively elsewhere in Indian MedTech policy coverage — has already prompted 19 greenfield medical device plants targeting high-end modalities that were previously almost entirely imported, directly easing supply bottlenecks for the cardiovascular devices market specifically.
Government health spending has also risen to 1.84% of GDP, alongside falling out-of-pocket healthcare spending — a combination that signals growing public purchasing power for devices, not just growing private demand. And the National Medical Devices Policy’s broader push toward domestic manufacturing, regulatory harmonisation, and reduced import dependence provides the structural backdrop against which “India for India” stent, catheter, and structural heart device manufacturing is being built.
Domestic Players Leading the Charge
Indian manufacturers have been building genuine international credibility in cardiovascular devices specifically, not just domestic market share. Sahajanand Medical Technologies (SMT), through its Supraflex stent platform, holds the distinction of being the first company in the world to receive CE certification for a drug-eluting stent with a biodegradable polymer — and has spent the past several years building an international regulatory track record to match, with its next-generation Supraflex Cruz stent recently clearing Health Canada’s demanding Class IV device licence and, separately, Egypt’s Drug Authority, extending SMT’s footprint into both North America and Africa within the same year.
That pattern — Indian-developed coronary devices clearing high-scrutiny international regulatory bars, not just competing domestically on price — is precisely the shift the PLI scheme and India’s broader “assembly to genuine value-addition” manufacturing push have been trying to accelerate. Alongside SMT, global majors including Abbott, Medtronic, Boston Scientific, Terumo, and Biotronik continue to expand their Indian manufacturing and distribution footprints, creating a genuinely competitive field of both domestic and multinational players building out India’s cardiovascular device supply.
What the Next 5 Years Likely Look Like
Putting the demographic, clinical, and policy threads together, a few reasonably confident projections emerge for India’s cardiovascular MedTech sector through the early 2030s:
Structural heart and peripheral vascular devices will outgrow the broader market considerably, given their substantially higher projected CAGRs (structural heart near 20%, peripheral vascular near 10%) relative to the blended cardiovascular devices average of roughly 6–9%. TAVR and LAAC specifically are likely to see accelerating hospital adoption beyond the current concentration in flagship metro cardiac centres.
Domestic manufacturing will continue closing India’s stent and catheter import gap, building on PLI-driven greenfield plant investment, though — consistent with the broader “assembly versus deep value-addition” tension flagged across India’s medical device manufacturing policy discussions — the pace at which this translates into genuine component-level manufacturing (rather than final-stage assembly) will determine how much of this growth actually reduces import dependence versus simply relocating final production steps domestically.
AI-assisted cardiac imaging will move from early adoption to standard practice at a faster pace than most other diagnostic AI categories, given cardiology’s existing reliance on image interpretation and the parallel infrastructure being built for AI diagnostics more broadly under India’s national AI healthcare roadmap.
Indian device makers will keep pursuing international regulatory credibility as a growth strategy, following the pattern SMT has set with back-to-back international approvals — a trend likely to extend to other Indian cardiovascular device manufacturers seeking export markets beyond India’s borders, not just domestic market share.
The Bottom Line
India’s cardiovascular devices market sits at a genuinely rare intersection: a disease burden that’s both growing and structurally distinctive (younger, more diffuse, harder to treat with imported, one-size-fits-all device designs), a clinical shift firmly toward minimally invasive and precision-guided intervention, and a policy environment actively subsidising the domestic manufacturing capacity needed to meet that demand affordably. Whether the market lands closer to the more conservative USD 2.3 billion estimates or the more bullish USD 4 billion-plus projections by the early 2030s, the underlying direction is consistent across every research estimate: sustained, multi-year growth, disproportionately concentrated in the minimally invasive, structural heart, and AI-assisted diagnostic categories where India’s clinical need and its manufacturing ambitions are now most clearly aligned.
References
- IMARC Group — India Cardiovascular Devices Market Size & Share 2034 (https://www.imarcgroup.com/india-cardiovascular-devices-market)
- Mordor Intelligence — India Cardiovascular Devices Market – Trends, Companies & Analysis (https://www.mordorintelligence.com/industry-reports/india-cardiovascular-devices-market-growth)
- TechSci Research — India Cardiovascular Devices Market Size and Growth Outlook 2030F (https://www.techsciresearch.com/report/india-cardiovascular-devices-market/8095.html)
- BlueWeave Consulting — India Cardiovascular Devices Market Booming at Healthy CAGR (https://www.blueweaveconsulting.com/press-release/india-cardiovascular-devices-market-booming-at-healthy-cagr-to-surpass-value-of-usd-1-6-billion-by-2030)
- Grand View Research — India Structural Heart Devices Market Size & Outlook, 2030 (https://www.grandviewresearch.com/horizon/outlook/structural-heart-devices-market/india)
- Grand View Research — India Peripheral Vascular Devices Market Size & Outlook, 2030 (https://www.grandviewresearch.com/horizon/outlook/peripheral-vascular-devices-market/india)
- ScienceDirect — Young Onset Coronary Artery Disease in India: A Descriptive Observational Study (https://www.sciencedirect.com/science/article/pii/S2213398424003488)
- Indian Heart Journal — Premature Coronary Artery Disease in India: Coronary Artery Disease in the Young (CADY) Registry (https://pmc.ncbi.nlm.nih.gov/articles/PMC5414957)
- Business Standard — Sahajanand Medical Technologies Secures Regulatory Approval in Egypt for Supraflex Cruz Coronary Stent (https://www.business-standard.com/content/press-releases-ani/sahajanand-medical-technologies-secures-regulatory-approval-in-egypt-for-supraflex-cruz-coronary-stent-126091600554_1.html)
Note: Market size and CAGR figures vary meaningfully across research providers due to differing scope definitions and should be read as directional ranges rather than a single authoritative figure. This article reflects publicly available market research and clinical literature as of September 2026.